New York, December 21, 2020 (GLOBE NEWSWIRE) – Reportlinker.com announces the report “Global Erythropoietin (EPO) Market Report 2020-30: Growth and Change COVID-19” – https://www.reportlinker .com / p05999219 /? utm_source = GNW
01 billion in 2019 to $ 0.95 billion in 2020 at a complex annual growth rate (CAGR) of -6.27%. The decline is largely due to the COVID-19 revolution that has led to limited containment measures including social distance, remote working, and the closure of businesses and other commercial activities leading to operational challenges. The entire supply chain was disrupted, adversely affecting the market. The market is then expected to recover and reach $ 2.27 billion in 2023 at a CAGR of 33.9%.
The erythropoietin (EPO) market includes the sale of erythropoietin drugs by organizations (organizations, single dealers, and partners) that make erythropoietin biosimilars. Erythropoietin (EPO) is a hormone secreted by the kidneys and plays a vital role in the production of red blood cells, which carry oxygen from the lungs to the rest of the body. Lack of adequate erythropoietin leads to low red blood cells, which can lead to anemia. The drugs erythropoietin (EPO) are used for the treatment of anemia, renal disorders, cancer and other conditions.
In August 2018, STADA Arzneimittel AG, a German-based pharmaceutical company, received majority commitments (51.34%) in Arzneimittel AG Bioceuticals for an undisclosed amount. The build is expected to expand STADA Arzneimittel AG’s presence in the other bios sector. Arzneimittel AG Bioceuticals grants marketing rights to epoetin zeta and epoetin bios similar to STADA Arzneimittel AG. Bioceuticals Arzneimittel AG is a German-based company engaged in the manufacture and marketing of active pharmaceutical products including erythropoietin biosimilars.
The erythropoietin market covered in this report is segregated by product to epoetin-alpha; epoetin-beta; darbepoetin-alfa; others and by the introduction of cancer; hematology; kidney diseases; neurology; others.
Strict regulations imposed on the manufacture and sale of erythropoietin drugs are expected to hamper the growth of the erythropoietin market over the expected period. For example, in the European Community (EC), technologically advanced medicines manufactured using a biotechnological process such as recombinant DNA technology should comply with marketing authority (MA) under the provisions of Regulation (EC) ) Ref. 726/04 issued by EC. The regulatory policy for biosimilars is complex and in Europe it is largely governed by directives issued by the European Medicines Agency (EMEA). In addition to this, reconstituted human erythropoietin (rHuEPO) requires additional specific product class guidelines as well as quality, clinical, and non-clinical quality regulations developed by the EMEA.
An increase in chronic kidney disease is expected to drive the market demand for erythropoietin over the coming years. According to Brazilian Journal of Nephrology statistics published in February 2019, kidney disease is a global public health care problem affecting more than 750 million people worldwide. In addition, according to a report of the Centers for Disease Control and Prevention published on kidney disease in the United States, in 2019, an estimated 15% of adults in the U.S., or 37 million people with chronic kidney disease (CKD). CKD is more common in people aged 65 or older (38%) than in people aged 45-64 years (13%) and 18-44 years (7%). Chronic renal disease leads to an anemic condition which in itself increases the demand for erythropoietin to reduce the condition, thus driving revenue for the market.
Read the full report: https://www.reportlinker.com/p05999219/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest business data so you can get all the market research you need – instantly, in one place.
__________________________
Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001